Oral Melphalan Therapy in Advanced Malignant Disease
Author Information
Author(s): Peter Clifford, R. A. Clift, J. H. Gillmore
Primary Institution: King George VI Hospital, Nairobi, Kenya
Hypothesis
Melphalan may be effective in treating various advanced malignant diseases, particularly melanoma and Burkitt's lymphoma.
Conclusion
Oral melphalan therapy showed dramatic responses in some cases of melanoma and Burkitt's lymphoma, with the longest remission lasting seven months.
Supporting Evidence
- Two cases of melanoma showed dramatic responses to melphalan therapy.
- Three cases of Burkitt's lymphoma also showed significant improvement.
- The longest remission lasted for seven months in one patient.
Takeaway
Doctors gave a medicine called melphalan to sick people with cancer, and some got better for a while.
Methodology
Melphalan was administered orally to 29 patients over a period of 4-5 days, with some receiving maintenance therapy.
Potential Biases
Potential bias due to the small number of cases and lack of control group.
Limitations
The study had a small sample size and varied responses to treatment, with some patients not responding at all.
Participant Demographics
Included 29 patients with various types of advanced malignancies, including melanoma and Burkitt's lymphoma.
Want to read the original?
Access the complete publication on the publisher's website